12-9　ⓔ文献

  1. 田中　篤：原発性硬化性胆管炎 (PSC) のup–to–date. 胆道，2018; 32: 241–250.

  2. Tanaka A, Mori M, et al: Increase trend in the prevalence and male–to–female ratio of primary biliary cholangitis, autoimmune hepatitis, and primary sclerosing cholangitis in Japan. Hepatol Res, 2019; 49: 881–889.

  3. Tanaka A, Tazuma S, et al: No negative impact of serum IgG4 levels on clinical outcome in 435 patients with primary sclerosing cholangitis from Japan. J Hepatobiliary Pancreat Sci, 2017; 24: 217–225.

  4. Karlsen TH, Folseraas T, et al: Primary sclerosing cholangitis: a comprehensive review. J Hepatol, 2017; 67: 1298–1323.

  5. Nakamoto N, Sasaki N, et al: Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis. Nat Microbiol, 2019; 4: 492–503.

  6. Isayama H, Tazuma S, et al: Clinical guidelines for primary sclerosing cholangitis 2017. J Gastroenterol, 2018; 53: 1006–1034.

  7. Lindor KD, Kowdley KV, et al: High–dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology, 2009; 50: 808–814.

  8. Mizuno S, Hirano K, et al: Prospective study of bezafibrate for the treatment of primary sclerosing cholangitis. J Hepatobiliary Pancreat Sci, 2015; 22: 766–770.

  9. 猪股裕紀洋，梅下浩司，他：肝移植症例登録報告．移植，2016; 51: 145–159.

  10. Egawa H, Ueda Y, et al: Risk factors for recurrence of primary sclerosing cholangitis after living donor liver transplantation in Japanese registry. Am J Transplant, 2011; 11: 518–527.

  11. 神澤輝実，中沢貴宏，他：IgG4関連硬化性胆管炎診療ガイドライン．胆道，2019; 33: 169–210.

  12. Tanaka A, Tazuma S, et al: Clinical features, response to treatment, and outcomes of IgG4–related sclerosing cholangitis. Clin Gastroenterol Hepatol, 2017; 15: 920–926. e3.

  13. Ohara H, Okazaki K, et al: Clinical diagnostic criteria of IgG4–related sclerosing cholangitis 2012. J Hepatobiliary Pancreat Sci, 2012; 19: 536–542.